What is Sales and Marketing Strategy of Jiangsu Hengrui Medicine Company?

What is the Sales and Marketing Strategy of Jiangsu Hengrui Medicine?

Jiangsu Hengrui Medicine is a prominent pharmaceutical firm that has strategically shifted towards developing innovative drugs and expanding globally. This pivot is underscored by significant recent collaborations, such as its July 2025 agreement with GSK, valued up to $12 billion, for the co-development of new medicines.

This strategic move emphasizes Hengrui's increasing international reach and its dedication to delivering advanced therapies worldwide. The company’s revenue grew from $3.88 billion USD in 2024 to $4.04 billion USD in 2025 (TTM), demonstrating strong financial performance.

The company's sales and marketing strategy focuses on highlighting its innovative drug portfolio, which saw sales of 13.892 billion yuan in 2024, a 30.60% increase year-on-year. These innovative products now constitute nearly 50% of its total revenue, acting as a primary growth driver. This includes advancements in areas like oncology and immunology, with products such as Jiangsu Hengrui Medicine BCG Matrix gaining traction.

Jiangsu Hengrui Medicine's sales strategy is built on a direct sales team model, focusing on engaging healthcare professionals and institutions. This approach is crucial for educating medical practitioners about their innovative therapies and ensuring widespread product adoption within the healthcare ecosystem.

Direct Sales Force Engagement

The company prioritizes a direct sales force to foster strong relationships with doctors and hospitals. This allows for in-depth product education and tailored support, which is vital for the successful launch and uptake of new pharmaceutical products.

Global Partnerships for Market Access

A key element of Hengrui Medicine's business strategy involves expanding its global reach through strategic partnerships and out-licensing agreements. These collaborations are instrumental in accessing international markets and accelerating the commercialization of its drug pipeline.

International Market Expansion

By the close of 2024, Hengrui's products were available in over 40 countries, underscoring a significant push for internationalization. The company continues to focus on developing its presence in emerging markets as part of its global marketing strategy.

Strategic Collaboration Example

A notable example of Hengrui Medicine's sales tactics for new drugs is the July 2025 agreement with GSK. This deal grants GSK rights to commercialize up to 12 of Hengrui's innovative medicines outside of China, leveraging GSK's extensive global infrastructure.

Accelerating Globalization and Revenue Diversification

These international collaborations are crucial for Hengrui Medicine's growth strategy, enabling access to major markets like North America and Europe. This approach not only diversifies revenue streams through milestone payments and royalties but also reduces capital exposure while accelerating global market penetration.

• Leveraging established global commercial infrastructure.
• Securing milestone payments and royalties on international sales.
• Reducing capital exposure for global market development.
• Accelerating the adoption of innovative therapies worldwide.

The company's market approach also involves a strategic reduction in its reliance on agency sales models. This shift is intended to enhance channel control and improve overall profitability, aligning with a more integrated Hengrui Medicine sales strategy. The effectiveness of Hengrui Medicine's sales force is a key consideration in its overall business strategy, ensuring efficient market coverage and strong customer relationships.

Complete Jiangsu Hengrui Medicine Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Jiangsu Hengrui Medicine's marketing tactics are deeply rooted in professional medical education and the dissemination of robust scientific data. The company prioritizes engaging healthcare professionals (HCPs) through various channels to build awareness and drive adoption of its pharmaceutical products. This strategic focus is crucial in the highly regulated pharmaceutical landscape.

Professional Medical Education

Hengrui Medicine heavily invests in educating healthcare professionals about its innovative treatments. This includes providing comprehensive clinical data and product information.

Scientific Data Dissemination

The company actively shares its research findings through medical conferences, academic exchanges, and publications. This establishes credibility and showcases product efficacy.

Digital Engagement

Hengrui is increasingly leveraging digital platforms to reach HCPs. This includes content marketing via online medical platforms and targeted digital advertising.

Omnichannel Approach

Recognizing the evolving digital habits of HCPs, Hengrui is developing omnichannel strategies. This aims to provide a seamless and integrated experience across various touchpoints.

R&D as a Marketing Tool

The company's significant investment in R&D, with a ratio of 15% to revenue in 2025 and over 5,500 R&D professionals, highlights its commitment to innovation. This inherently serves as a powerful marketing differentiator.

Market Access and Affordability

Inclusion of innovative drugs like Rezvilutamide and Camrelizumab in national medical insurance coverage is a key marketing advantage. This enhances accessibility and affordability for patients.

The Jiangsu Hengrui Medicine sales strategy is multifaceted, focusing on building strong relationships with healthcare providers and demonstrating the value of its innovative therapies. The company's approach to marketing its products is tailored to the specific needs of the pharmaceutical market, emphasizing scientific evidence and professional engagement. Understanding how Jiangsu Hengrui Medicine markets its products reveals a commitment to both scientific advancement and strategic market penetration. This comprehensive Marketing Strategy of Jiangsu Hengrui Medicine outlines the core components of their market approach.

Key Marketing Tactics

Hengrui Medicine employs a range of marketing tactics designed to reach and influence its target audience within the pharmaceutical sector.

• Direct engagement with healthcare professionals (HCPs) through medical conferences and academic exchanges.
• Dissemination of clinical trial data and scientific publications to support product claims.
• Leveraging digital channels for content marketing and targeted advertising to HCPs.
• Exploring and implementing omnichannel strategies for enhanced HCP engagement.
• Highlighting R&D investment and innovation as a key selling proposition.
• Utilizing national medical insurance coverage to improve drug accessibility and affordability.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Jiangsu Hengrui Medicine has established its brand positioning as a premier global biopharmaceutical entity, driven by a commitment to scientific advancement and human health. The company's core ethos, encapsulated by 'Innovation, Pragmatism, Focus, Diligence,' guides its mission to conquer diseases and enhance lives.

Innovation-Driven Pipeline

The company's primary differentiator lies in its substantial R&D capabilities and a robust pipeline of innovative drugs, particularly in oncology. This focus on groundbreaking treatments is central to its market approach.

Addressing Unmet Needs

Hengrui Medicine appeals to healthcare professionals, institutions, and patients by actively addressing critical unmet medical needs. This dedication aims to significantly improve patient outcomes worldwide.

Significant R&D Investment

The company's commitment to innovation is evidenced by its substantial R&D investments, exceeding $5 billion in recent years. By the close of 2024, it was actively engaged in approximately 400 clinical trials for over 90 innovative drug candidates.

Global Recognition and Reach

Hengrui Medicine has garnered international acclaim, appearing on Pharma Exec's Top 50 pharmaceutical companies list for six consecutive years since 2019. In 2024, it secured 8th place on Citeline's 'Top 25 Global Pharma Companies by Pipeline Size'.

The company's brand consistency is reinforced through its unwavering focus on high-quality, innovative medicines and its expanding global presence, with products available in over 40 countries by the end of 2024. Furthermore, the inclusion of its innovative drugs, such as Rezvilutamide, in China's National Reimbursement Drug List (NRDL) enhances patient access and affordability, solidifying its market appeal. Understanding the competitive landscape is crucial for appreciating Hengrui Medicine's strategic positioning; for insights into this, refer to the Competitors Landscape of Jiangsu Hengrui Medicine.

Oncology Leadership

Oncology represents Hengrui Medicine's dominant therapeutic area, showcasing its specialized expertise and market leadership in this critical field.

Patient-Centric Mission

The company's mission to serve patients by striving to conquer diseases, improve health, and extend lives is a cornerstone of its brand identity and marketing efforts.

Global Market Penetration

With products commercialized in over 40 countries by the end of 2024, Hengrui Medicine demonstrates a strong global market penetration strategy for its innovative pharmaceuticals.

R&D Investment Impact

The significant R&D investment directly fuels the company's ability to bring novel therapies to market, a key driver of its sales strategy and competitive advantage.

Accessibility through NRDL

Inclusion in the NRDL in China for key drugs like Rezvilutamide enhances patient access and affordability, a crucial element of its market approach in the region.

Pipeline Strength

Ranking 8th globally in pipeline size in 2024 underscores the depth and breadth of Hengrui Medicine's future product offerings, a vital component of its long-term brand building.

Jiangsu Hengrui Medicine Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Key campaigns for Jiangsu Hengrui Medicine are strategically focused on driving innovation and global expansion, particularly within the oncology sector. These initiatives leverage significant R&D investments to develop novel therapies and secure international partnerships, underscoring a robust Jiangsu Hengrui Medicine sales strategy.

Global Out-Licensing and Strategic Partnerships

A major campaign involves global out-licensing deals, exemplified by the July 2025 partnership with GSK. This collaboration aims to develop and commercialize up to 12 innovative medicines, including HRS-9821 for COPD.

Focus on Innovative Oncology Therapies

Hengrui Medicine's marketing strategy heavily emphasizes its innovative oncology drug, Rezvilutamide. This drug has achieved significant market penetration in China, capturing 30% of the AR inhibitor market in 2025.

Market Penetration and Accessibility

Rezvilutamide's success is bolstered by its cost-effectiveness and inclusion in China's National Reimbursement Drug List (NRDL), enhancing patient access and demonstrating effective market penetration strategy.

R&D Investment as a Foundation

The company's consistent R&D investment, totaling 8.228 billion yuan in 2024 (29.40% of revenue), is a core element supporting all product-specific marketing campaigns and driving the Hengrui Medicine business strategy.

Global Partnership Value

The GSK deal, with potential future payments up to $12 billion, highlights Hengrui's growing global influence and the value of its pipeline, contributing to China's out-licensing deals representing 32% of global deals in H1 2025.

Oncology Revenue Growth

Innovative drug revenue reached 13.892 billion yuan in 2024, a 30.60% increase, with oncology drugs being a primary driver, showcasing strong Hengrui Medicine pharmaceutical sales.

Competitive Pricing and Access

Rezvilutamide's market success is a testament to Hengrui Medicine's market approach, balancing scientific innovation with strategic pricing to compete effectively against imported alternatives.

High Gross Margin in Oncology

The oncology segment boasts a gross margin as high as 92.57%, indicating efficient production and strong pricing power, a key factor in Hengrui Medicine's sales tactics for new drugs.

R&D Investment Impact

The substantial R&D investment directly fuels the development of innovative therapies, underpinning Hengrui Medicine's R&D investment impact on sales and its overall competitive advantage.

Global Marketing Strategy

The strategic out-licensing deals are integral to Hengrui Medicine's global marketing strategy, expanding the reach of its innovative products and enhancing its international presence.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE